drugset / Trial / NCT00179283

Sertraline vs. Venlafaxine XR

NCT00179283

Phase 3 Completed 20 enrolled Vanderbilt University Pfizer · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, active control, 8-week, flexible dose study of sertraline vs. venlafaxine Extended Release in the acute treatment of Major Depression in male and female outpatient sites that will recruit 15-20 patients each. Subjects will be randomized in a 1:1 ratio to receive either sertraline or venlafaxine XR based on a computer-generated randomized list.

Timeline

Start
2002-04
Primary completion
Completion
2003-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Sertraline Small molecule 150 mg
Subject Venlafaxine Small molecule 225 mg